This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 7 of 15 for:    Chimerix

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Expanded access is currently available for this treatment.
Verified December 2016 by Chimerix
Sponsor:
Information provided by (Responsible Party):
Chimerix
ClinicalTrials.gov Identifier:
NCT02596997
First received: November 3, 2015
Last updated: December 7, 2016
Last verified: December 2016
  Purpose
Provide patients with serious AdV infection or disease access to treatment with BCV.

Condition Intervention
Adenovirus Drug: Brincidofovir

Study Type: Expanded Access     What is Expanded Access?
Official Title: An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Further study details as provided by Chimerix:

Intervention Details:
    Drug: Brincidofovir
    Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
    Other Name: BCV CMX001
  Eligibility

Ages Eligible for Study:   2 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
  • Able to swallow medication, either tablet or liquid

Exclusion Criteria:

  • Previous dosing with Brincidofovir
  • If female, not pregnant or trying to become pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02596997

Contacts
Contact: Garrett Nichols, MD 919-287-6006 gnichols@chimerix.com

  Show 38 Study Locations
Sponsors and Collaborators
Chimerix
  More Information

Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT02596997     History of Changes
Other Study ID Numbers: CMX001-351
Study First Received: November 3, 2015
Last Updated: December 7, 2016

Keywords provided by Chimerix:
Adenovirus Brincidofovir

Additional relevant MeSH terms:
Adenoviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on August 18, 2017